Resumo Objetivo Comparar o uso de mirabegrom com anticolinérgicos para o tratamento da bexiga hiperativa (BH). Fonte de Dados Buscas sistemáticas foram realizadas nas bases de dados EMBASE, PUBMED, Cochrane e LILACS desde o início até setembro de 2021. Incluímos ECR, mulheres com sintomas de BH clinicamente comprovados, estudos que compararam mirabegrom a medicamentos antimuscarínicos e avaliaram a eficácia, segurança ou adesão. Coleta de Dados RevMan 5.4 foi usado para combinar os resultados entre os estudos. Derivamos razões de risco (RRs) e diferenças médias com intervalo de confiança (IC) de 95% usando um modelo meta-analítico de efeitos aleatórios. Cochrane Collaboration Tool e GRADE foi aplicado para risco de viés e qualidade da evidência. Síntese dos Dados Foram incluídos 14 estudos com um total de 10.774 pacientes. Menos eventos adversos totais foram relatados no grupo mirabegrom do que no grupo antimuscarínicos [RR: 0,93 (0,89–0,98)]. O risco de distúrbios do trato gastrointestinal e boca seca foram menores com mirabegrom [RR: 0,58 (0,48–0,68); 9.375 pacientes; RR: 0,44 (0,35–0,56), 9.375 pacientes, respectivamente]. Nenhuma diferença foi relatada entre mirabegrom e drogas antimuscarínicos para eficácia. A adesão ao tratamento foi de 87,7% em ambos os grupos [RR: 0,99 (0,98–1,00)]. Conclusão Mirabegrom e antimuscarínicos têm eficácia e taxas de adesão comparáveis, porém o mirabegrom apresentou menos eventos adversos totais e isolados. BH. . (BH) EMBASE PUBMED 2021 ECR comprovados 54 5 4 5. RRs (RRs IC (IC 95 metaanalítico meta analítico aleatórios evidência 1 10774 10 774 10.77 pacientes RR [RR 093 0 93 0,9 0,89–0,98. 089098 0,89–0,98 89 98 (0,89–0,98)] 058 58 0,5 0,48–0,68 048068 48 68 (0,48–0,68) 9375 9 375 9.37 044 44 0,4 0,35–0,56, 035056 0,35–0,56 , 35 56 (0,35–0,56) respectivamente. respectivamente respectivamente] 877 87 7 87,7 099 99 0,98–1,00. 098100 0,98–1,00 00 (0,98–1,00)] comparáveis isolados (BH 202 1077 77 10.7 09 0, 08909 0,89–0,9 8 (0,89–0,98) 05 0,48–0,6 04806 6 (0,48–0,68 937 37 9.3 04 03505 0,35–0,5 3 (0,35–0,56 87, 09810 0,98–1,0 (0,98–1,00) 20 107 10. 0890 0,89–0, (0,89–0,98 0,48–0, 0480 (0,48–0,6 9. 0350 0,35–0, (0,35–0,5 0981 0,98–1, (0,98–1,00 2 089 0,89–0 (0,89–0,9 0,48–0 048 (0,48–0, 035 0,35–0 (0,35–0, 098 0,98–1 (0,98–1,0 08 0,89– (0,89–0, 0,48– (0,48–0 03 0,35– (0,35–0 0,98– (0,98–1, 0,89 (0,89–0 0,48 (0,48– 0,35 (0,35– 0,98 (0,98–1 0,8 (0,89– (0,48 0,3 (0,35 (0,98– (0,89 (0,4 (0,3 (0,98 (0,8 (0, (0,9 (0 (
Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events. OB. . (OB) EMBASE PUBMED 2021 RCTs symptoms 54 5 4 5. RRs (RRs 95 randomeffects random effects metaanalytic meta analytic model evidence 1 10774 10 774 10,77 patients 093 0 93 0.9 0.89–0.98. 089098 0.89–0.98 89 98 (0.89–0.98)] 058 58 0,5 0.48–0.68 048068 48 68 (0.48–0.68) 937 044 44 0.4 0.35–0.56, 035056 0.35–0.56 , 35 56 (0.35–0.56) respectively. respectively respectively] 877 87 7 87.7 099 99 0.98–1.00. 098100 0.98–1.00 00 (0.98–1.00)] rates however (OB 202 9 1077 77 10,7 09 0. 08909 0.89–0.9 8 (0.89–0.98) 05 0, 0.48–0.6 04806 6 (0.48–0.68 04 03505 0.35–0.5 3 (0.35–0.56 87. 09810 0.98–1.0 (0.98–1.00) 20 107 10, 0890 0.89–0. (0.89–0.98 0.48–0. 0480 (0.48–0.6 0350 0.35–0. (0.35–0.5 0981 0.98–1. (0.98–1.00 2 089 0.89–0 (0.89–0.9 0.48–0 048 (0.48–0. 035 0.35–0 (0.35–0. 098 0.98–1 (0.98–1.0 08 0.89– (0.89–0. 0.48– (0.48–0 03 0.35– (0.35–0 0.98– (0.98–1. 0.89 (0.89–0 0.48 (0.48– 0.35 (0.35– 0.98 (0.98–1 0.8 (0.89– (0.48 0.3 (0.35 (0.98– (0.89 (0.4 (0.3 (0.98 (0.8 (0. (0.9 (0 (